CaaS Capital is a Series B to Series C stage investment firm based in New York, New York, United States. It has made 6 investments, with focus areas including Biotech & Life Sciences. 100% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-c (67% of deals). Average disclosed round size is $105.2M (across 6 rounds with reported amounts).
Portfolio
6
Fund Size
$971.0M
Top Stage
Series C
Last 12 Mo
0
Team
DH
Dr. Hua Yi
Managing Director
SQ
Saif Qazi
Vice President
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
6 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Umoja Biopharma | Series C | $100M | Jan 2025 |
 HotSpot Therapeutics, Inc. | Series C | $100M | Nov 2021 |
 Artios Pharma Limited | Series C | $153M | Jul 2021 |
 StrideBio, Inc. | Series B | $81.5M | Mar 2021 |
 Amunix Pharmaceuticals, Inc. | Series B | $117M | Mar 2021 |
 Cyteir Therapeutics | Series C | $80M | Feb 2021 |
Top Co-Investors
Avidity Partners3 shared
Janus Henderson Investors2 shared
Venrock2 shared
Omega Funds2 shared
RTW Investments2 shared
Alexandria Venture Investments2 shared
LSP2 shared
Sofinnova Partners2 shared
RA Capital Management1 shared
Ally Bridge Group1 shared
Novo Holdings1 shared
Lightstone Ventures1 shared
Osage University Partners1 shared
Viking Global Investors1 shared
Bain Capital Life Sciences1 shared
BlackRock1 shared
Franklin Templeton1 shared
ArrowMark Partners1 shared
Redmile Group1 shared
Casdin Capital1 shared
Last updated: 8 March 2026